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Abstract 
Background: Chronic inflammation of the airways is a central component in lung diseases and is frequently associ-
ated with bacterial infections. Monitoring the pro-inflammatory capability of bacterial virulence factors in vivo is chal-
lenging and usually requires invasive methods.
Methods: Lung inflammation was induced using the culture supernatants from two Pseudomonas aeruginosa clinical 
strains, VR1 and VR2, isolated from patients affected by cystic fibrosis and showing different phenotypes in terms of 
motility, colony characteristics and biofilm production as well as pyoverdine and pyocyanine release. More interest-
ing, the strains differ also for the presence in supernatants of metalloproteases, a family of virulence factors with 
known pro-inflammatory activity. We have evaluated the benefit of using a mouse model, transiently expressing the 
luciferase reporter gene under the control of an heterologous IL-8 bovine promoter, to detect and monitoring lung 
inflammation.
Results: In vivo imaging indicated that VR1 strain, releasing in its culture supernatant metalloproteases and other 
virulence factors, induced lung inflammation while the VR2 strain presented with a severely reduced pro-inflam-
matory activity. The bioluminescence signal was detectable from 4 to 48 h after supernatant instillation. The animal 
model was also used to test the anti-inflammatory activity of azithromycin (AZM), an antibiotic with demonstrated 
inhibitory effect on the synthesis of bacterial exoproducts. The inflammation signal in mice was in fact significantly 
reduced when bacteria grew in the presence of a sub-lethal dose of AZM causing inhibition of the synthesis of metal-
loproteases and other bacterial elements. The in vivo data were further supported by quantification of immune cells 
and cytokine expression in mouse broncho-alveolar lavage samples.
Conclusions: This experimental animal model is based on the transient transduction of the bovine IL-8 promoter, a 
gene representing a major player during inflammation, essential for leukocytes recruitment to the inflamed tissue. It 
appears to be an appropriate molecular read-out for monitoring the activation of inflammatory pathways caused by 
bacterial virulence factors. The data presented indicate that the model is suitable to functionally monitor in real time 
the lung inflammatory response facilitating the identification of bacterial factors with pro-inflammatory activity and 
the evaluation of the anti-inflammatory activity of old and new molecules for therapeutic use.
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Background
Airway inflammation is a central component of a number 
of chronic lung diseases such as asthma, chronic obstruc-
tive pulmonary disease (COPD), cystic fibrosis (CF) and 
bronchiectasis. Airway inflammation is characterized 
by edema, cellular infiltration, activated T lymphocytes 
and mast cells, increased airway secretions, and deposi-
tion of excess collagen [1, 2]. Frequently, the inflamma-
tion is associated with bacterial infections such as those 
caused by Pseudomonas aeruginosa, an opportunistic 
human pathogen involved in severe airway infections 
especially in patients suffering from CF and COPD [1, 3]. 
During the early onset of the lung infection, P. aeruginosa 
secretes a high number of virulence factors which are 
responsible for tissue damage and inflammation [4]. As 
the infection progresses, the bacterium switches off most 
of the virulence genes but synthesizes a biofilm matrix 
and becomes resistant to antibiotics causing a chronic 
disease frequently leading to respiratory failure and lung 
transplantation or death [4].
Therefore, it is mandatory to identify those factors and 
conditions causing lung cell damage and favoring the 
passage from an acute to a chronic bacterial infection by 
monitoring, for long times, the inflammation process. 
Furthermore, to avoid the onset of the chronic phase of 
the infection, it is important to treat P. aeruginosa infec-
tion during the acute phase using efficient antibiotic ther-
apy and anti-inflammatory drugs.
By standard methods, the inflammation of the respira-
tory tract can be monitored by counting immunological 
markers recruited during the inflammatory process with 
sputum collection, a technique which provides poorly 
reliable results, or invasive sampling techniques such as 
bronchoscopy [5]. Animal models of acute and chronic 
lung infection have been used to study the bacterial 
behavior and for monitoring the host response in  vivo 
[1, 6]. These models provide an important resource to 
identify essential bacterial genes for in  vivo infection 
persistence and for the development and testing of new 
therapies [6, 7]. Recently, a mouse model, transiently 
expressing the luciferase reporter gene under the con-
trol of the bovine IL-8 promoter, has been described [8] 
and demonstrated to be suitable to functionally monitor 
in real time the lung inflammatory response [8–11]. This 
small size experimental animal model is based on the 
transient transduction of the IL-8 promoter, a gene rep-
resenting a major player during inflammation, essential 
for leukocytes recruitment to the inflamed tissue and an 
appropriate molecular read-out for monitoring the acti-
vation of inflammatory pathways [8]. Although mice do 
not have an IL-8 (bIL-8) gene, mouse cell signaling and 
their transcriptional apparatus could specifically acti-
vate the bovine IL-8 gene promoter. Since lung disease 
manifestation in ruminants overlap with the majority of 
human lung disease manifestations, this model could be 
of great value to study human lung diseases too.
It has been shown that the P. aeruginosa strains iso-
lated during the early phase of lung colonization had a 
pro-inflammatory capability higher than that induced 
by strains isolated during lung chronic colonization [12]. 
The pro-inflammatory effect, associated with the expres-
sion of IL-8 mRNA in CF airway epithelial cells, was 
shown to be associated to several Pseudomonas released 
proteins with proteolytic activity including members 
of the metalloprotease (MP) family [12]. Other viru-
lence factors secreted by Pseudomonas such as exotox-
ins and exoenzymes, pyoverdine and pyocianine are also 
involved in tissue damage and inflammation. It has been 
suggested that azithromycin (AZM), an antibiotic used 
in CF patients, could elicit its anti-inflammatory activity 
by decreasing the synthesis of Pseudomonas exoproducts 
[13–15]. In fact, Molinari et al. [13] have shown that sub-
lethal doses of AZM strongly suppressed the synthesis 
of elastase, lecithinase, proteases and DNase, while in 
another study it has been shown that AZM reduced the 
production of bacteria virulence factors by inhibiting 
quorum-sensing [15].
In the present study, we used the IL-8/luciferase trans-
genic mouse model for the in vivo monitoring of the IL-8 
mediated lung inflammation induced by P. aeruginosa 
secreted pro-inflammatory virulence factors and their 
modulation by AZM.
Methods
Collection of bacterial cell‑free supernatants
Two P. aeruginosa strains, VR1 and VR2, were isolated 
from sputum samples of CF patients followed at the 
Cystic Fibrosis Center in Verona, Italy and were char-
acterized for their differential expression of known 
virulence factors (data summarized in Fig.  1). Writ-
ten informed consent was obtained from the subjects 
enrolled in the study and approved by the Institutional 
Review Board of Azienda Ospedaliera Universitaria Inte-
grata (AOUI) Verona as project 1612.
Bacterial strains were grown overnight at 37°C in 
Bacto™ Tryptic Soy Broth (TSB, Becton, Dickinson and 
Company) with continuous agitation. The day after, P. 
aeruginosa cells were diluted in TSB to the concentration 
of 1 × 108 CFU/mL (OD of 0.1 at 600 nm) and incubated 
in absence and in presence of 8 µg/mL of AZM, at 37°C 
for 16  h with continuous agitation. The concentration 
chosen for this antibiotic is in the sub-minimum inhibi-
tory concentration (sub-MIC) range for P. aeruginosa, 
and is consistent with the concentrations found in lungs 
of patients treated with this drug [16]. By adding TSB, 
the cultures were normalized to an optical density of 0.2 
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OD at 600 nm. Culture supernatants (Sn) were collected 
by centrifugation (7,000×g, 30  min, 4°C) and filtered 
through a 0.22 µm Millipore filter to remove any remain-
ing bacteria. Supernatants were concentrated to 30X 
using Amicon Ultra-15 30 K (Millipore, Billerica, USA), 
then centrifuged at 27,000×g for 1 h at 4°C to remove cel-




P. aeruginosa VR1 and VR2 isolates were grown on Luria 
Bertani  (LB) agar plates for 24–48 h at 37°C and colony 
morphotypes were visually inspected for color, shape, 
edges regularity, and mucoidy.
Motility assays
Swimming plates (1 % tryptone, 0.5 % NaCl and 0.3 % 
(w/v) agar) were point-inoculated from an overnight cul-
ture with a sterile toothpick and incubated at 37°C for 
24  h. The zone diameter was measured to assess swim-
ming motility.
Swarming plates (0.5% peptone, 0.3% yeast extract, 
0.5% NaCl, 0.5% d-glucose and 0.5% (w/v) agar) were 
point-inoculated from an overnight culture with a ster-
ile toothpick and incubated at 37°C for 24  h. Swarming 
motility was assessed by measuring the circular turbid 
zones formed by the bacterial cells migrating away from 
the point of inoculation.
Twiching motility was evaluated on LB 1% (w/v) agar 
plates. Overnight cultures were stabbed with a ster-
ile toothpick through the agar layer to the bottom of 
the Petri dish. The plates were then incubated at 37°C 
for 48  h. Twiching motility was examined by measur-
ing the diameter of the halo formed in the plastic-agar 
interface.
Biofilm formation assay
Bacterial cells were grown at 37°C in TSB-1% glucose 
until they reached the exponentially growing phase 
(OD650nm = 0.4). Exponentially growing cells were then 
diluted in TSB-1% glucose medium to reach 106 CFU/
mL. Two hundred microliter of each cell suspension 
were used to inoculate sterile flat-bottomed polystyrene 
microtiter plates (CytoOne, Starlab) and plates were 
incubated aerobically at 37°C without agitation for 48 h 
to allow biofilm formation. After incubation, the plank-
tonic cells were aseptically aspirated, washed with sterile 
physiological solution and dried. For biofilm quantifica-
tion, 100  µL of 1% methylene blue were added to each 
well and the plate maintained for 15 min at room tem-
perature. The wells were subsequently slowly washed 
once with sterile water and dried at 37°C. The methyl-
ene blue bound to the biofilm was extract using 100 µL 
of 70% ethanol and the absorbance measured at 570 nm 
using “A3 Plate Reader” microplate reader (DAS Srl, 
Italy). All the mentioned experiment were performed in 
triplicate.
Virulence factors and phenotypes P. aeruginosa strain   
VR1
P. aeruginosa strain   
VR1 + AZM
P. aeruginosa strain  
VR2
P. aeruginosa strain  
VR2 + AZM
Metallo-proteases +++ + - -
Pyocianin
µg/ml 0,29 0,16 0,12 0,13
Relative conc. 
(OD550/OD600)
0,048 0,026 0,020 0,022
Pyoverdine µg/ml 2,63 0,00 0,13 0,06
Relative conc. 
(OD550/OD600)
0,103 0,00 0,005 0,002
Colony phenotype
Colour Green Light brown Light brown Light brown
Mucoidy No No Yes Yes
Edges Jagged Jagged Regular Regular
Morphology Swarming Swarming Round Round
Biofilm production +++ ND ++ ND
Twiching ( cm) 0,8 0,7 0,6 0,8
Swimming ( cm) 2,3 1,2 0,5 0,5
Swarming ( cm) 1,6 1,2 0,3 0,4
Fig. 1 Phenotypic characteristics and virulence factors of the P. aeruginosa clinical strains.
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Virulence factor assays
The presence of virulence factors in culture supernatants 
was evaluated after growth of the bacterial strains with 
and without AZM.
Gelatin‑zymography for analysis of the protease profile
We used gelatin-zymography to investigate the pres-
ence of total metalloprotease activity, by visualization 
of clear bands (areas of gelatin digestion) over a deep 
blue background after Coomassie staining. Five millili-
tres of 5X SDS sample buffer (5% SDS, 0.5 M Tris–HCl 
pH 6.8, 25% glycerol) were added to 20  µL of culture 
supernatants. The sample was run on a SDS-PAGE 
gel containing 1  mg/mL gelatin (Sigma-Aldrich) as 
described [12]. In order to compare metalloproteases 
expression/release by the different strains, for each 
sample we loaded equal aliquots of culture superna-
tants normalized to a 0.2 final OD after overnight 
growth starting from 0.1 OD. The gel was washed 
twice (20  min per cycle) with 2.5% Triton X-100 at 
room temperature, then incubated in 200  mL of acti-
vation buffer (10  mM Tris–HCl, 1.25% Triton X-100, 
5  mM CaCl2, 1  mM ZnCl2) overnight at 37°C and 
finally stained with Coomassie Brilliant Blue G-250 in 
20% methanol/10% phosphoric acid/10% ammonium 
sulfate and destained in water. Gel images were cap-
tured by ImageQuant LAS 4000 (GE Healthcare Life 
Sciences, Milan, Italy).
Western blot analysis of alkaline metalloprotease AprA
Proteins were precipitated from 12 mL of culture super-
natants by addition of 10% (final concentration) trichlo-
roacetic acid with stirring at 4°C. The sample was then 
centrifuged at 3,000g for 30  min and washed 3 times 
with an excess of acetone:methanol (8:1). The pellet 
was air-dried, resuspended in SDS sample buffer, sub-
jected to SDS-PAGE and Western blotting as described 
[12]. Briefly, protein bands were transferred from 
the 10% acrylamide gel onto a nitrocellulose mem-
brane (HybondTM ECLTM, Amersham, NJ, USA), 
using a mini trans-blot apparatus (Bio-Rad, Califor-
nia, USA) following the manufacturer’s instructions. 
The membrane was incubated with a 1:500 dilution of 
purified rabbit IgG against P. aeruginosa alkaline pro-
tease (AprA), a kind gift from G. Döring (University of 
Tübingen, Germany), in TBS-T with 1% BSA overnight 
at 4°C. The blot was washed four times in TBS-T and 
then incubated for 1 h at room temperature with don-
key anti-rabbit IgG secondary antibody conjugated to 
horseradish peroxidase (Amersham, NJ, USA) diluted 
1:15,000 in TBS-T with 1% BSA. Bound proteins were 
visualized using the ECL detection system (Millipore 
Corporation, Bedford, MA, USA).
In vitro imaging probe
A near infrared (NIR)-activatable “smart” probe (Per-
kin Elmer, Inc. Boston, MA, USA) was used for imaging 
protease activities. Specifically, MMPsense 750 FAST is 
a proteases activatable fluorescent in vivo imaging agent 
that is activated by key disease associated-proteinases 
such as MMPs including MMP-2, -3, -9 and -13 and bac-
terial proteases. Smart probes are optically silent in their 
inactivated state and becomes highly fluorescent follow-
ing protease-mediated activation.
The MMPsense 750 FAST probe was added to 50 μL 
of culture supernatants at the final concentration of 0.02 
nmoles in a 96-well plate and an imaging system (IVIS, 
Caliper Life Sciences, Alameda, CA, USA) was used to 
quantify the time course of the fluorescence every 30  s 
from 1 to 40 min.
Pyoverdine assay
The production of pyoverdine by P. aeruginosa was 
measured spectrophotometrically by a modification of 
a standard method. Overnight cultures of the strains 
were diluted to an optical density at 600 nm (OD600) of 
0.1 in 30 mL of King’s B broth (low-iron medium) with 
and without 8  µg/mL AZM and grown at 37°C until 
they reached an OD600 of ≈2–3 (after 16  h). Cultures 
were normalized to OD600 of 0.2 in order to reproduce 
the conditions of supernatants used for mice stimu-
lation. The absorbance of cell-free supernatants was 
measured at 405  nm. The concentration of pyover-
dine was calculated by using the extinction coefficient 
(1.9 × 10−4 M−1 cm−1).
Pyocyanin assay
The pyocyanin assay is based on the absorbance of pyo-
cyanin at 520  nm in acidic solution (Essar et  al. 1990). 
Bacterial cultures were grown in LB medium with or 
without AZM following the same conditions described 
for pyoverdine assay. Five milliliters of cell-free super-
natants were extracted with 3  mL of chloroform. The 
lower phase was mixed with 1 mL of 0.2 M HCl, and the 
absorbance of the resulting upper pink phase was meas-
ured at 520  nm (A520). Concentration, expressed as μg 
of pyocyanin per millilitre of culture supernatant, was 
determined by multiplying the A520 value by 17.072.
Experimental animals
Female inbred BalbC (7–8  week-old) mice were pur-
chased from Harlan Laboratories Italy (San Pietro al 
Natisone, Udine, Italy). Prior to use, animals were accli-
matized for at least 5  days to the local vivarium condi-
tions (room temperature: 20–24°C; relative humidity: 
40–70%; 12-h light–dark cycle), having free access to 
standard rodent chow and softened tap water. Animal 
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experiments were conducted in compliance with national 
(Decreto Legislativo numero 26, 4 Marzo 2014) and 
international laws and policies (Guide for the Care and 
Use of Laboratory Animals) [17]. Animal studies were 
approved by the Institutional Animal Care and Use Com-
mittee at Chiesi Farmaceutici, Parma, Italy.
In vivo gene delivery
The bIL-8-Luc plasmid (Department of Medical Veteri-
nary Science, University of Parma, Italy) was obtained 
by sub-cloning the 2,030  bp IL8 bovine promoter, 
amplified by PCR from Madin–Darby bovine kidney 
(MDBK; ATCC #CCL-22) genomic DNA and sub-
cloned into the digested pGL3basic vector (Promega) 
as previously described [8]. We applied in  vivo JetPEI 
(Polyplus Transfection) as a carrier for delivering DNA 
to lung tissues. The DNA and JetPEI mix was formu-
lated according to the product manual with a final N/P 
ratio of 7. Briefly, 40 μg of bIL-8–luc and 7 μL of Jet-
PEI were both diluted into 200 μL 5% glucose. The two 
solutions were then mixed and incubated for 15  min 
at room temperature. The entire mixture was injected 
intravenously into BalbC mice and the expression of 
bIL-8–Luc was monitored through imaging with an 
IVIS imaging system.
In vivo bioluminescence imaging
Transfection per se causes a mild lung inflammatory 
response and bIL-8 activation that is detectable by bio-
luminescence imaging (BLI) up to 3–4  days after DNA 
injection and disappears completely after 1 week [11].
One week after DNA delivery, the transient transgenic 
mice were injected intraperitoneally (i.p.) with luciferin 
(150 mg/kg) and BLI was recorded in order to check the 
baseline activation of the IL-8 pathway. Briefly, 10 and 
15  min following luciferin injection, mice were lightly 
anesthetized with isoflurane and images were obtained 
using the IVIS imaging system: an average of photons 
emitted from the chest of the mice was quantified using 
Living Image® software (Caliper Life Sciences, Alameda, 
CA, USA). The following day, mice were intratracheally 
challenged with 10X supernatants and BLI was recorded 
at 4, 24, and 48  h.  Data were expressed as mean folds 
of induction (FOI) over the baseline activation of each 
mouse.
Bronchoalveolar lavage and cytokine
Twenty-four hours after intratracheal challenge, animals 
were weighted, anaesthetized with isoflurane and sac-
rificed by bleeding from the abdominal aorta for bron-
choalveolar lavage fluid (BALF) collection, performed as 
previously described [8]. BALF supernatants were fro-
zen at −80°C for simultaneous quantitation of multiple 
cytokines/chemokines using a Bio-Plex™ Cytokine Assay 
Kit (Bio-Rad Laboratories, Segrate, Milano, Italy).
The cell pellet was suspended in 0.2  mL of PBS and 
total and differential cell counts were obtained using 
an automated cell counter (Dasit XT 1800J, Cornaredo; 
Milano, Italy).
Reagents
In vivo JetPEI DNA transfection reagent (Polyplus Trans-
fection) was obtained from Euroclone (Milan, Italy), 
d-luciferin was obtained from Perkin Elmer Inc. (Boston, 
MA, USA). AZM was from Pfizer (Italy).
Data analysis
Experimental values were expressed as the mean and 
standard error of the mean (SEM). Statistical analysis was 
performed using one-way analysis of variance followed 
by Dunnett’s t test (* p < 0.05, ** p < 0.01).
Results
Phenotypic characterization of Pseudomonas aeruginosa 
clinical isolates
We have previously characterized by large-scale prot-
eomic analysis the proteins released by different P. aer-
uginosa strains and have demonstrated their different 
capability to induce pro-inflammatory factors in bron-
chial epithelial cells [12]. For this study, we selected two 
P. aeruginosa strains, VR1 and VR2, isolated from two 
patients affected by CF and showing significant differ-
ences as regards phenotypic characteristics and release 
of various established virulence factors. The phenotypic 
characterization of the two strains is shown in Fig. 1. VR1 
and VR2 differentiate for the production of pyoverdin 
and pyocyanin which are released only in the VR1 super-
natant, the capability of moving by swimming, swarm-
ing and twitching detectable in VR1 but non in VR2, the 
production of biofilm which is more evident in VR1 with 
respect to VR2 and by the level of protease activity, well 
detectable in the VR1 supernatant and very reduced in 
the VR2 one.
Culture supernatants were prepared from the bacte-
rial strains by growing them in a culture medium in the 
absence (SnVR1 and SnVR2) and in the presence of a sub-
MIC dose of AZM (SnVR1 + AZM and SnVR2 + AZM). 
The inhibitory action of AZM on the expression of viru-
lence factors is clearly shown in Fig. 1. Culture superna-
tants were tested for the presence of proteolytic activity 
by a proteases activatable fluorescent probe (Fig. 2) and 
by zymography (Fig. 3b). The specific inhibitory effect of 
AZM on metalloprotease synthesis used as a marker of 
the efficacy of the treatment was also demonstrated by 
testing cell lysate and supernatants for the presence of 
proteolytic activity with a proteases activable fluorescent 
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probe (Fig.  2) and by zymography and western blotting 
specific for the P. aeruginosa metalloprotease, AprA 
(Fig. 3). 
In vivo monitoring of lung inflammation induced  
by P. aeruginosa culture supernatants in IL‑8 transiently 
transgenic mice
In vivo monitoring of lung inflammation after intratra-
cheal challenge with P. aeruginosa SnVR1 and SnVR2 at 
1X, 3X, 10X and 30X concentrations was carried out by 
in  vivo imaging in bIL-8 luc transient transgenic mice. 
Administration of the 10X SN concentration was suf-
ficient to induce the maximal increase in BLI signal. In 
fact, the use of the 30X Sn preparation did not translate 
into a higher inflammation signal, indicating a saturation 
of the system at lower concentration (10X) (Fig. 4a). For 
this reason, further experiments were conducted using 
10X concentration.
SnVR1 pro-inflammatory activity was clearly detectable 
as soon as 4  h post instillation, although the BLI signal 
reached the highest peak at 24 h (FOI 5.11 ± 1.07) and 
was still detectable at 48 h even if there is no statistical 
difference among the different groups (Fig.  4b). On the 
contrary, the SnVR2 did not induce detectable inflamma-
tion in the mouse lung at any time point. The BLI signal 
induced by the challenge with SnVR1 + AZI was signifi-
cantly lower (FOI 1.58 ± 0.21) after 24 h with respect to 
the response induced by SnVR1 obtained from the same 
bacterial strain grown without the antibiotic (Fig. 4b).
Recruitment of inflammatory cells and cytokine activation 
induced by P. aeruginosa culture supernatants
Twenty-four hours after mice stimulation with P. aer-
uginosa products, BALF was recovered from bIL-8 
transgenic animals treated with both VR1 and VR2 
supernatants in order to compare their effect on cell 
recruitment and cytokine expression. SnVR1, contain-
ing a series of important virulence factors, significantly 
stimulated total white blood cells (WBC) and neu-
trophils recruitment (respectively 6.52  ×  103  ±  0.44 
Fig. 2 Protease activity of cell-free supernatants from Pseudomonas aeruginosa grown in the presence and the absence of azithromycin. MMPsense 
750 FAST was added to supernatants from VR1 and VR2 strains grown in presence or absence of AZM (SnVR1 ± AZM and SnVR2 ± AZM) concen-
trated 1X, 10X and 30X. IVIS imaging system has been used to quantify the time course of the fluorescence. Data were expressed as induction folds 
over baseline (bacterial growth medium TSB). Results are reported as mean ± SEM and significance attributed when P < 0.05 (*) or P < 0.01 (**).







         -              +              -             + 
VR1 VR2 
Culture supernatants ba
Fig. 3 Analysis of metalloproteases activity and synthesis in VR1 and VR2 bacterial lysates and culture supernatants. MPs activity and synthesis are 
downregulated in VR1 + AZM and absent in VR2, both in lysates (a) and supernatants (b), as shown by zymography and western blot specific for 
AprA.
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and 4.19  ×  103  ±  0.43 cells/µL) and the expression of 
cytokines IL-1β, TNF-α, IL-17, RANTES, KC, IL 12 
(p70) and IL 12 (p40) (Figs.  5, 6). Inflammatory cells 
(WBC 2.39  ±  0.23  ×  103 and neutrophils recruitment 
1.70 ± 0.0.22 × 103 cells/µL) and expression of the cited 
cytokines were lower in SnVR2 with respect to SnVR1. 
SnVR2 showed a comparable effect on the release of 
RANTES and IL 12 (p40). 
BALF was recovered also from bIL-8 transgenic mice 
stimulated with SnVR1 +  AZM and SnVR2 +  AZM in 
order to evaluate the effect of the antibiotic on the pro-
inflammatory activity of both preparations. The chal-
lenge with SnVR1  +  AZM stimulated at a significant 
lower level WBC and neutrophils recruitment (respec-
tively 4.07 ± 0.39 × 103 and 2.05 ± 03.4 × 103 cells/µL) 
(Fig. 5) and the expression of the cytokines IL-1β, IL-17, 
RANTES, KC and IL-12 (p70) but not that of TNF-α 
and IL 12 (p40) in comparison with animals treated 
with SnVR1 (Fig. 6). A significant difference between the 
stimulation caused by SnVR2 and SnVR2  +  AZM was 
not observed except for RANTES and IL12-(p40) level 
(Fig. 6).
Conclusions
The mechanisms and mediators that drive the induction 
























Fig. 4 In vivo imaging of lung inflammation induced by P. aeruginosa culture supernatants on IL-8 transiently transgenic mice. a Representative 
images of mice (n = 3 per group) transiently transgenized with bIL-8-Luc and intratracheally instilled with bacterial cell-free 1X, 3X, 10X and 30X 
supernatants from VR1. The growth medium TSB was used as a control. Mice were monitored at 4, 24 and 48 h post stimulation by BLI drawing a 
region of interest (ROI) over the chest. b Representative images of mice (n = 8 per group) transiently transgenized with bIL-8-Luc and intratracheally 
instilled with bacterial cell-free, 10X supernatants from VR1 and VR2 strains grown in presence or absence of AZM (VR1 ± AZM and VR2 ± AZM). The 
growth medium TSB was used as a control. Mice were monitored at 4, 24 and 48 h post stimulation by BLI drawing a region of interest (ROI) over 
the chest. Data are also presented as light intensity quantification of the ROI using the LivingImage software. The experiment was repeated 3 times 
and each point represents the mean ± standard error of 8 animals. Data were expressed as FOI over baseline activity of each mice and statistical 
differences were tested by one way ANOVA followed by Dunnett’s post hoc test for group comparisons. Results are reported as mean ± SEM and 
significance attributed when P < 0.05 (*) or P < 0.01 (**).
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function in a series of human diseases are not completely 
understood and this has severely hampered the devel-
opment of effective treatments [1–3]. Although most 
of the animal models do not exactly mimic human lung 
diseases and each model has its own benefits and defi-
ciencies, animal models that accurately reflect human 
disease pathophysiology continue to be essential for 
the understanding of pathogenic aspects as well as the 
development and validation of new therapies. In most 
mammalian models, TNFα, IL-1β, and IL-8 are central 
components of a complex cytokine network that initiates, 
amplifies, and sustains the inflammatory response in 
tissue [18]. Available evidence also supports the impor-
tance of this network in coordinating acute inflammatory 
responses within the lung. The mouse model used in this 
study, transiently transgenized with a luciferase reporter 
gene under the control of the IL-8 bovine promoter, can 
be easily employed for modeling and monitoring human 
lung inflammation due to the high similarity existing 
between respiratory diseases in ruminants and humans 
without the high costs and demands in terms of mainte-
nance of ruminant models [8].
In the present study, the IL8/luciferase mouse model 
has been applied to the in  vivo monitoring of lung 
inflammation induced by virulence factors released by 
Pseudomonas aeruginosa and to the evaluation of the 
anti-inflammatory action of AZM as an inhibitor of the 
synthesis of bacterial factors involved in pathogenicity. 
Data here presented show that the P. aeruginosa clini-
cal strain  VR1, isolated from early lung colonization in 
a CF patient, synthesizes flagella and biofilm, produces 
and releases pyocyanin and pyoverdine and proteins 
with metallo-protease activity. The synthesis and release 
of these virulence factors significantly decreases when 
bacteria were grown in the presence of AZM. The pro-
inflammatory effect of strain VR1 has been shown in 
IL-8/luciferase transiently transgenic mice by applying 
in  vivo imaging and further confirmed by the increase 
in WBC and neutrophils recruitment and cytokine lev-
els in the airways of transgenized mice. On the contrary, 
the supernatant from bacteria grown in the presence of 
AZM, a condition associated with a much lower produc-
tion of virulence factors, stimulated the inflammatory 
response only at a very reduced level. Similar low lev-
els of IL-8 promoter activation was observed when the 
supernatant of the P. aeruginosa VR2 strain, lacking the 
specific virulence factors, was instilled in the airways of 
IL-8/luciferase transgenized mice.
These data support the notion that the clinical benefits 
associated to AZM treatment in CF patients might be at 
least in part due to the lowering of the exoproduct syn-
thesis induced by the antibiotic in bacterial cells.
Data obtained in this study demonstrate that the 
model here described is suitable to non-invasive real 
time monitoring of lung inflammatory response to bacte-
rial products and to confirm and better understand the 
mechanism of action of AZM (or any other compound 
of interest), an antibiotic frequently used in the therapy 
of CF. The non invasive nature of this mouse model and 
the possibility for bIL-8-luc transiently transgenized 
mice to be stimulated with bacterial products for long 
times [8] enables the monitoring of a biological process 
longitudinally in the same mouse and represents an obvi-














































Fig. 5 Immune cell recruitment during lung inflammation caused by P. aeruginosa supernatants. Cellular infiltration into the lung of mice 
intratracheally instilled with bacterial cell-free 10X supernatants from VR1 and VR2 strains grown in presence or absence of AZM (VR1 ± AZM and 
VR2 ± AZM). TSB is the bacterial growth medium and was used as a control. The amount of white blood cells and neutrophils found in BALF was 
expressed as number of cells per μl at 24 h post treatment. The experiment was repeated 3 times and each point represents the mean ± standard 
error of 8 animals. Results are reported as mean ± SEM and significance attributed when P < 0.05 (*) or P < 0.01 (**).
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studies. The model might be adapted and applied to 
study the pathogenesis of lung inflammatory diseases 
such as CF, to identify bacterial/nonbacterial factors with 
pro-inflammatory activity and to predict the possible 
therapeutic effect of known and new molecules with a 
presumptive anti-inflammatory action.
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Fig. 6 Cytokines concentration in mice BALF after stimulation with P. aeruginosa culture supernatants. Cytokine levels in BALF of bIL-8 transgenized 
mice 24 h after intratracheally challenge with bacterial cell-free supernatants from VR1 and VR2 strains grown in presence or absence of AZM 
(VR1 ± AZM and VR2 ± AZM). Data were expressed as FOI over the control (bacterial growth medium TSB) The experiment was repeated 3 times 
and each point represents the mean ± standard deviation of 8 animals. Results are reported as mean ± SEM and significance attributed when 
P < 0.05 (*) or P < 0.01 (**).
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